The median radiographic progression-free survival was 4.6 years in patients who received stereotactic body radiotherapy and 2.3 years in patients who did not. Adding metastasis-directed stereotactic ...
New guidelines on stereotactic body radiotherapy for primary renal cell carcinoma address optimal dosing, the role of biopsy, follow-up practices, and the treatment of patients with a solitary kidney.
Department of Radiological and Imaging Sciences performed its first case of stereotactic radiosurgery (SRS) using advanced ...
The American Society for Radiation Oncology (ASTRO) has issued new guidelines on the appropriate use of stereotactic radiation (SBRT) in early-stage non-small cell lung cancer (NSCLC), now the leading ...
Hosted on MSN
At 10 years, stereotactic body radiation therapy comparable to surgery for early-stage lung cancer
Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...
Maastricht, the Netherlands - A new technique using urokinase to liquefy intracerebral hematoma (ICH) followed by stereotactic drainage is safe and produced a "modest" reduction in the amount of ...
Stereotactic body radiotherapy as salvage therapy after radical prostatectomy was well tolerated. Toxic effects were comparable to a historical cohort of patients receiving conventionally fractionated ...
Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study. Administration of radiotherapy in conjunction with hormone treatment has ...
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results